We report the case of a 12-year-old child who was admitted to our Department, with 7 days' history of high fever and splenomegaly. His father had similar symptoms starting on the same day. A rapid test and microscopy for malaria yielded a positive result for Plasmodium vivax. Antimalarial therapy was initiated. He developed methemoglobinemia treated with ascorbic acid and had uneventful recovery.
C A S E P R E S E N T A T I O N
A 12-year-old Greek boy presented to the emergency department early October with a week history of fever, shaking chills and non-productive cough. Fever appeared daily during afternoon and persisted for about 12 h despite administration of antipyretics. During his disease course, fever worsened, eventually reaching a maximum of 41 C. He reported headache, loss of appetite and prostration. When afebrile, the patient was feeling well. On the fifth day of disease, he visited his pediatrician, who prescribed amoxicillin-clavulanate without clinical improvement. One day before admission, he developed substernal and abdominal pain.
His medical history was unremarkable. He reported no recent travel. He lives in the Marathon area in East Attica, in a small village approximately 40 km from the center of Athens, which is located next to the Marathon National Park (Fig. 1) , a wetland area. His father also had similar symptoms starting on the same day. On admission, the patient was febrile and feeling unwell. His physical examination revealed axillary temperature of 39.5 C, while other vital signs were normal. His liver and spleen were palpable, and sensitivity in the upper right and left abdominal quadrant was noted. His initial laboratory evaluation revealed normocytic, normochromic V C The Author [2016] . Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com anemia (Hematocrit 32.2%, Hemoglobin (Hb) 11.4 g/dl, mean corpuscular volume 74.4 fl, reticulocyte count 0.59%), a normal white cell count (5770/ml) and thrombocytopenia (PLT 120 000/ml). Chest radiography, urinalysis, liver function tests, bilirubin, renal function tests and coagulation tests were within normal range. Lactate dehydrogenase was 302 U/l, ESR was 42 mm and CRP 91.5 mg/l. Ultrasonography confirmed liver and spleen enlargement (16.5 cm and 16.5 Â 5.2 cm, respectively). Two sets of blood cultures and a urine culture were negative. Serology for EBV, CMV, Brucella, Toxoplasma and Leishmania was negative. Microscopic examination of bone marrow aspirate was negative for Leishmania amastigotes, as was a rapid detection test for the Leishmania rk39 antigen in peripheral blood (Leishmania Strip quick test, Cypress Diagnostics, Belgium).
The patient continued to be febrile. On the third hospital day, a rapid test for malaria was performed (SD BIOLINE Malaria Ag P.f./Pan. Standard Diagnostics, Republic of Korea) that yielded a positive result for the pan-malaria antigen and a negative for Plasmodium falciparum. Consequently, Plasmodium vivax was identified by microscopy of a Giemsa-stained thin smear, based on the morphological characteristics of trophozoites. The diagnosis was confirmed by polymerase chain reaction. Chloroquine therapy was initiated at a dose of 10 mg/kg. Following glucose-6-phosphate dehydrogenase (G6PD)-level assessment, as shown by the Guthrie test, Primaquine 0.5 mg base/kg was added to the therapeutic regimen. He improved and remained afebrile from the second day of treatment. He developed nausea and vomiting, a known side effect of chloroquine for which he was treated successfully with ondansetron and esomeprazol.
On the third day of treatment, a decreased oxygen saturation was observed, ranging from 88% to 91%. There was no dyspnea but facial pallor was observed. Arterial capillary blood gas analysis was within normal range and revealed an oxygen saturation of 99.8%. Spirometry was normal. Administration of oxygen was initiated with no improvement of O 2 saturation. Abnormality of oxygen transport resulting from the presence of a pathological Hb was suspected. The blood methemoglobin (MetHb) concentration was measured by arterial blood gas analysis and found elevated (9.4%). Treatment with ascorbic acid was initiated and he remained symptom free for the remainder of his hospitalization. MetHb levels were determined daily and values ranged from 10 to 10.8. The patient was discharged after completion a 14 day course of primaquine treatment.
His father, a farmer, was diagnosed with P. vivax infection elsewhere and treated with chloroquine and primaquine. They both, had been spending a considerable amount of time outdoors in their fields, often during the evening. Considering that they both fell ill on the same day, one may postulate that they were infected within the same time frame, possibly from a common source. Unfortunately, the paternal blood sample was sent to our laboratory after the initiation of treatment and tested negative for Plasmodium.
D I S C U S S I O N A N D C O N C L U S I O N S
Malaria was a common disease in Greece since antiquity; until mid-1940s, three Plasmodium species were considered endemic, while regular epidemics of P. falciparum affected thousands every year [1] . Following the eradication program, implemented in 1946, Greece achieved malaria-free status in 1974. Since then, malaria in Greece has been mostly imported, with the identity of imported strains reflecting the area of original infection. Notwithstanding, only a few introduced sporadic cases of locally transmitted P. vivax malaria during the 1990s and 2000s have been reported. Since 2009, however, locally transmitted P. vivax malaria began to appear-as sporadic introduced cases and as clusters (in 2011-12)-in certain geographic areas in Greece collectively amounting to 79 locally transmitted cases (7 of which involved children <14 years old) until October 2015 [2] . The prefecture of East Attica, where the Marathon Municipality is located is an area from which autochthonous introduced P. vivax malaria cases have been annually reported (1-4 cases/year), from 2009 to 2012, and in 2015. Malaria introduction and maintenance in a given area depends on (i) the feasibility of malaria transmission in the area, which is relevant to environmental and climatic conditions, mainly humidity and temperature, enabling vector presence and survival and (ii) the presence of a human reservoir of the disease that will infect the vector. The patients' possible place of exposure is located next to the Marathon National Park, a wetland with fresh, salty and brackish water and wet meadows an ecological niche conducive to the development and multiplication of mosquitoes. Several anopheline mosquito species are widely distributed in Greece, including Anopheles sacharovi, Anopheles maculipennis, Anopheles superpictus and Anopheles claviger. The mosquito fauna of the Marathon area has been recently studied, revealing a predominance (99%) of A. sacharovi, an efficient malaria vector and the one that was mainly responsible for disease transmission in Greece in the preeradication era [3] .
Regarding the presence of an infected human reservoir, a massive influx of immigrants from Africa and Asia into Greece has occurred in recent years. Large immigrant worker populations were invariably present in most foci of documented local malaria transmission to date. Immigrants are mostly employed as farm workers, poorly housed in an environment favoring man-mosquito contact and sparsely if at all using health care services, owing to their common undocumented status. In view of P. vivax gametogenesis occurring rapidly in the course of infection, it is reasonable to assume that these untreated foreign patients are the reservoir for local mosquito infection. A recent study that genotyped imported and locally acquired P. vivax strains, isolated from various areas of Greece indicated that a substantial number of P. vivax strains were imported into various foci in Greece, some of which were consequently transmitted from infected mosquitoes to the local population [4] . Furthermore, a few of those resurfaced in autochthonous cases in the following year, raising the risk of sustained local transmission in a certain area (HCDCP unpublished data). The risk of local transmission in an area located <50 km from Athens, is a contingency warranting increased surveillance and immediate implementation of prevention and control measures.
Primaquine is used in cases of P. vivax malaria, to eliminate persistent liver forms (hypnozoites). This drug is a powerful inducer of MetHb even with normal, G6PD activity, transforming Hb (Fe2þ), which is essential for oxygen transport, into reduced Hb (Fe3þ) within erythrocytes. Within the normal red blood cell, a small amount of MetHb can be present, but this is continuously reduced to Hb by action of the NADH-diaphorase (cytochrome b5 reductase) enzyme, which normally keeps the MetHb level <1%. When MetHb in blood increases to > 2%, the condition is known as methemoglobinemia [5] . MetHb levels <20% are not associated with respiratory symptoms in most people. In our case, only facial pallor was observed. MetHb levels of 30% are commonly associated with dyspnea, nausea and tachycardia; up to 55% are associated with lethargy and stupor; over 55% MetHb results in cardiac arrhythmia and CNS depression. Levels of MetHb >70% are generally considered fatal [6] . Hb is very sensitive to oxidative stress, and a G6PD deficit increases this sensitivity, resulting in more pronounced methemoglobinemia when such patients are given primaquine. Nevertheless, methemoglobinemia is routinely observed even in individuals with normal G6PD activity. It is feasible to administer primaquine whenever required, but only after previous fulfillment of three simple criteria: normal G6PD activity, in white, non-pregnant subjects and with a light meal. Under these conditions, the major adverse effect after administration of this drug, serious methemoglobinemia is rare, but adverse events at even the highest daily dose are short-lived, mild and without long-term side effects [6] .
One may suggest measurement of MetHb levels during treatment in patients with decreased oxygen saturation or respiratory symptoms to prevent this potentially severe side effect. To conclude, malaria should be included in the differential diagnosis of febrile patients without travel history and even in the absence of a typical tertian or quartan fever pattern, especially in case of residence or visit to areas of known recent local malaria transmission. Moreover, pallor during primaquine treatment should prompt oxygen saturation testing and MetHb in cases with desaturation.
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